Routine use of recombinant human bone morphogenetic protein-2 in posterior fusions of the pediatric spine and incidence of cancer

Journal of Neurosurgery: Pediatrics

Volumn 16, Issue 1, 2015, Pages 4-13

  Sayama, Christina ^a,b   Willsey, Matthew ^a,b   Chintagumpala, Murali ^a   Brayton, Alison ^a,b   Briceño, Valentina ^a,b   Ryan, Sheila L ^a,b   Luerssen, Thomas G ^a,b   Hwang, Steven W ^c,d   Jea, Andrew ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone morphogenetic protein; Cancer; Complications; Malignancy; Neurosurgery; Oncology; Pediatric spine; RhBMP 2; Spinal fusion; Spinal instrumentation; Technique

Indexed keywords

COLLAGEN SPONGE; PROPOFOL; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN-2; RECOMBINANT PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ADOLESCENT; ADULT; ARTICLE; BONE GRAFT; CANCER GROWTH; CANCER INCIDENCE; CANCER RISK; CAUSE OF DEATH; CELLULITIS; CERVICAL SPINE; CHILD; COHORT ANALYSIS; COMPLETE THORACIC PARAPLEGIA; DEEP VEIN THROMBOSIS; DEVICE FAILURE; DISEASE EXACERBATION; DISTAL JUNCTIONAL KYPHOSIS; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; FEMALE; FOLLOW UP; HEART FAILURE; HEPATOMEGALY; HETEROTOPIC OSSIFICATION; HUMAN; IMPAIRED PROPRIOCEPTION; INFANT; KIDNEY FAILURE; KYPHOSIS; LIVER FAILURE; LUMBAR SPINE; LUMBOSACRAL SPINE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MEDICAL DEVICE COMPLICATION; METABOLIC ACIDOSIS; METASTASIS; MYELITIS; NECK SWELLING; OCCIPTOCERVICAL SPINE; PNEUMOTHORAX; POSTERIOR NECK SWELLING; POSTERIOR SPINE FUSION; POSTOPERATIVE COMPLICATION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPOFOL INFUSION SYNDROME; REOPERATION; RESTENOSIS; RETROSPECTIVE STUDY; SCHOOL CHILD; SEROMA; SIDE EFFECT; SOFT TISSUE DEFECT; SPINAL CANAL RESTENOSIS; SPINE IMPLANT; SUPERFICIAL WOUND; THORACIC SPINE; TREATMENT OUTCOME; WOUND INFECTION; YOUNG ADULT; ATLANTOOCCIPITAL JOINT; INCIDENCE; LUMBAR VERTEBRA; NEOPLASMS; PROCEDURES; RISK ASSESSMENT; RISK FACTOR; SACRUM; SPINE FUSION; SURGERY; UNITED STATES; VERTEBRA;

ADOLESCENT; ADULT; ATLANTO-OCCIPITAL JOINT; BONE MORPHOGENETIC PROTEIN 2; CERVICAL VERTEBRAE; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INFANT; LUMBAR VERTEBRAE; MALE; NEOPLASMS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SACRUM; SPINAL FUSION; TEXAS; THORACIC VERTEBRAE; TRANSFORMING GROWTH FACTOR BETA; YOUNG ADULT;

EID: 84964694124     PISSN: 19330707     EISSN: 19330715     Source Type: Journal    
DOI: 10.3171/2014.10.PEDS14199     Document Type: Article

References (42)

1. Allen RT, Lee Y P, Stimson E, Garfin SR: Bone morphogenetic protein-2 (BMP-2) in the treatment of pyogenic vertebral osteomyelitis. Spine (Phila Pa 1976) 32:2996-3006, 2007
2. Blanco JS, Sears CJ: Allograft bone use during instrumentation and fusion in the treatment of adolescent idiopathic sco-liosis. Spine (Phila Pa 1976) 22:1338-1342, 1997
3. Boden SD, Zdeblick TA, Sandhu HS, Heim SE: The use of rhBMP-2 in interbody fusion cages. Definitive evidence of osteoinduction in humans: a preliminary report. Spine (Phila Pa 1976) 25:376-381, 2000
4. Boyne PJ, Marx RE, Nevins M, Triplett G, Lazaro E, Lilly LC, et al: A feasibility study evaluating rhBMP-2/absorbable collagen sponge for maxillary sinus floor augmentation. Int J Periodontics Restorative Dent 17:11-25, 1997
5. Burkus JK, Gornet MF, Dickman CA, Zdeblick TA: Anterior lumbar interbody fusion using rhBMP-2 with tapered interbody cages. J Spinal Disord Tech 15:337-349, 2002
6. Burkus JK, Gornet MF, Schuler TC, Kleeman TJ, Zdeblick TA: Six-year outcomes of anterior lumbar interbody arthrodesis with use of interbody fusion cages and recombinant human bone morphogenetic protein-2. J Bone Joint Surg Am 91:1181-1189, 2009
7. Cahill KS, Chi JH, Day A, Claus EB: Prevalence, complications, and hospital charges associated with use of bonemorphogenetic proteins in spinal fusion procedures. JAMA 302:58-66, 2009
8. Cahill PJ, Warnick DE, Lee MJ, Gaughan J, Vogel LE, Hammerberg KW, et al: Infection after spinal fusion for pediatric spinal deformity: thirty years of experience at a single institution. Spine (Phila Pa 1976) 35:1211-1217, 2010
9. Carlisle E, Fischgrund JS: Bone morphogenetic proteins for spinal fusion. Spine J5 (6 Suppl):240S-249S, 2005
10. Carragee EJ, Hurwitz EL, Weiner BK: A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J11:471-491, 2011
11. Czitrom A: Biology of bone grafting and principles of bone banking, in Weinstein SL (ed): The Pediatric Spine: Principle and Practice. New York: Raven Press, 1994, pp 1285-1298
12. Devine JG, Dettori JR, France JC, Brodt E, McGuire RA: The use of rhBMP in spine surgery: is there a cancer risk? Evid Based Spine Care J3:35-41, 2012
13. Dimar JR II, Glassman SD, Burkus JK, Pryor PW, Hardacker J W, Carreon LY: Clinical and radiographic analysis of an optimized rhBMP-2 formulation as an autograft replacement in posterolateral lumbar spine arthrodesis. J Bone Joint Surg Am 91:1377-1386, 2009
14. Fahim DK, Whitehead WE, Curry DJ, Dauser RC, Luerssen TG, Jea A: Routine use of recombinant human bone morphogenetic protein-2 in posterior fusions of the pediatric spine: safety profile and efficacy in the early postoperative period. Neurosurgery 67:1195-1204, 2010
15. FDA Summary of Safety and Effectiveness Data (INFUSE® Bone Graft). Silver Springs: Food and Drug Administration, 2007 (http://www.accessdata.fda.gov/cdrh-docs/pdf5/P050053b.pdf) [Accessed December 19, 2014]
16. Fu R, Selph S, McDonagh M, Peterson K, Tiwari A, Chou R, et al: Effectiveness and harms of recombinant human bone morphogenetic protein-2 in spine fusion: a systematic review and meta-analysis. Ann Intern Med 158:890-902, 2013
17. Hansen SM, Sasso RC: Resorptive response of rhBMP2 simulating infection in an anterior lumbar interbody fusion with a femoral ring. J Spinal Disord Tech 19:130-134, 2006
18. Ho C, Skaggs DL, Weiss JM, Tolo VT: Management of infection after instrumented posterior spine fusion in pediatric scoliosis. Spine (Phila Pa 1976) 32:2739-2744, 2007
19. Iantosca MR, McPherson CE, Ho SY, Maxwell GD: Bone morphogenetic proteins-2 and -4 attenuate apoptosis in a cerebellar primitive neuroectodermal tumor cell line. J Neurosci Res 56:248-258, 1999
20. Ide H, Yoshida T, Matsumoto N, Aoki K, Osada Y, Sugimura T, et al: Growth regulation of human prostate cancer cells by bone morphogenetic protein-2. Cancer Res 57:5022-5027, 1997
21. Itoh K, Udagawa N, Katagiri T, Iemura S, Ueno N, Yasuda H, et al: Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-xB ligand. Endocrinology 142:3656-3662, 2001
22. Kanatani M, Sugimoto T, Kaji H, Kobayashi T, Nishiyama K, Fukase M, et al: Stimulatory effect of bone morphogenetic protein-2 on osteoclast-like cell formation and bone-resorbing activity. J Bone Miner Res 10:1681-1690, 1995
23. Labbé AC, Demers AM, Rodrigues R, Arlet V, Tanguay K, Moore DL: Surgical-site infection following spinal fusion: a case-control study in a children's hospital. Infect Control Hosp Epidemiol 24:591-595, 2003
24. Lad SP, Bagley JH, Karikari IO, Babu R, Ugiliweneza B, Kong M, et al: Cancer after spinal fusion: the role of bone morphogenetic protein. Neurosurgery 73:440-449, 2013
25. Linam WM, Margolis PA, Staat MA, Britto MT, Hornung R, Cassedy A, et al: Risk factors associated with surgical site infection after pediatric posterior spinal fusion procedure. Infect Control Hosp Epidemiol 30:109-116, 2009
26. Lind M, Eriksen EF, Bünger C: Bone morphogenetic protein-2 but not bone morphogenetic protein-4 and -6 stimulates chemotactic migration of human osteoblasts, human marrow osteoblasts, and U2-OS cells. Bone 18:53-57, 1996
27. Lu DC, Sun PP: Bone morphogenetic protein for salvage fusion in an infant with Down syndrome and craniovertebral instability. Case report. J Neurosurg 106 (6 Suppl):480-483, 2007
28. Mackenzie WG, Matsumoto H, Williams BA, Corona J, Lee C, Cody SR, et al: Surgical site infection following spinal instrumentation for scoliosis: a multicenter analysis of rates, risk factors, and pathogens. J Bone Joint Surg Am 95:800-806, 2013
29. Meyer RA Jr, Gruber HE, Howard BA, Tabor OB Jr, Murakami T, Kwiatkowski TC, et al: Safety of recombinant human bone morphogenetic protein-2 after spinal laminectomy in the dog. Spine (Phila Pa 1976) 24:747-754, 1999
30. O'Shaughnessy BA, Kuklo TR, Ondra SL: Surgical treatment of vertebral osteomyelitis with recombinant human bone morphogenetic protein-2. Spine (Phila Pa 1976) 33:E132-E139, 2008
31. Poynton AR, Lane JM: Safety profle for the clinical use of bone morphogenetic proteins in the spine. Spine (Phila Pa 1976) 27 (16 Suppl 1):S40-S48, 2002
32. Sandhu HS, Kanim LE, Kabo JM, Toth JM, Zeegan EN, Liu D, et al: Evaluation of rhBMP-2 with an OPLA carrier in a canine posterolateral (transverse process) spinal fusion model. Spine (Phila Pa 1976) 20:2669-2682, 1995
33. Schimandle JH, Boden SD, Hutton WC: Experimental spinal fusion with recombinant human bone morphogenetic protein-2. Spine (Phila Pa 1976) 20:1326-1337, 1995
34. Shields LB, Raque GH, Glassman SD, Campbell M, Vitaz T, Harpring J, et al: Adverse effects associated with highdose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion. Spine (Phila Pa 1976) 31:542-547, 2006
35. Simmonds MC, Brown J V, Heirs MK, Higgins JP, Mannion RJ, Rodgers MA, et al: Safety and effectiveness of recombinant human bone morphogenetic protein-2 for spinal fusion: a meta-analysis of individual-participant data. Ann Intern Med 158:877-889, 2013
36. Smucker JD, Rhee JM, Singh K, Yoon ST, Heller JG: Increased swelling complications associated with off-label usage of rhBMP-2 in the anterior cervical spine. Spine (Phila Pa 1976) 31:2813-2819, 2006
37. Soda H, Raymond E, Sharma S, Lawrence R, Cerna C, Gomez L, et al: Antiproliferative effects of recombinant human bone morphogenetic protein-2 on human tumor colony-forming units. Anticancer Drugs 9:327-331, 1998
38. Subach BR, Haid RW, Rodts GE, Kaiser MG: Bone morphogenetic protein in spinal fusion: overview and clinical update. Neurosurg Focus 10(4):E3, 2001
39. Tada A, Nishihara T, Kato H: Bone morphogenetic protein 2 suppresses the transformed phenotype and restores actin microflaments of human lung carcinoma A549 cells. Oncol Rep 5:1137-1140, 1998
40. Thawani J P, Wang AC, Than KD, Lin CY, La Marca F, Park P: Bone morphogenetic proteins and cancer: review of the literature. Neurosurgery 66:233-246, 2010
41. Toth JM, Boden SD, Burkus JK, Badura JM, Peckham SM, McKay WF: Short-term osteoclastic activity induced by locally high concentrations of recombinant human bone morphogenetic protein-2 in a cancellous bone environment. Spine (Phila Pa 1976) 34:539-550, 2009
42. Vitale MG, Riedel MD, Glotzbecker M P, Matsumoto H, Roye DP, Akbarnia BA, et al: Building consensus: development of a best practice guideline (BPG) for surgical site infection (SSI) prevention in high-risk pediatric spine surgery. J Pediatr Orthop 33:471-478, 2013